Compositions Comprising Immune System Activators and Method of Using Same

Patent metadata

Field	Value
Publication number	US-2021047646-A1
Application number	US-201917044195-A
Country	US
Kind code	A1
Filing date	Apr 9, 2019
Priority date	Apr 9, 2018
Publication date	Feb 18, 2021
Grant date	—

Abstract

The present invention relates, in various embodiments, to compositions comprising synthetic DNA molecules, and methods of using such compositions to enhance an immune response to cancer, for example, by activating the RNase L pathway in cells without inducing immunosuppressive effects caused by other agents that are known to activate this pathway.

First claim

1 . A composition comprising a DNA oligonucleotide molecule, wherein the DNA oligonucleotide molecule comprises:
a) two or more phosphorothioate linkages; and b) a 2′-O-methyl RNA base at the 5′ end, the 3′ end or both the 5′ and 3′ ends of the oligonucleotide molecule; wherein the DNA oligonucleotide molecule comprises at least one strand of more than 10 contiguous deoxyribonucleotide bases.

2 . The composition of claim 1 , wherein the DNA oligonucleotide molecule comprises a deoxyribonucleotide sequence that is not identical to a mammalian genomic deoxyribonucleotide sequence of the same length.

3 . The composition of claim 1 , wherein the DNA oligonucleotide molecule comprises a deoxynucleotide sequence that has less than 50% identity to a mammalian genomic deoxyribonucleotide sequence of the same length.

4 . The composition of claim 1 , wherein the DNA oligonucleotide molecule comprises a phosphorothioate linkage between each of the nucleotide bases in at least one of the strands of the DNA oligonucleotide molecule.

5 . The composition of claim 1 , wherein the DNA oligonucleotide molecule comprises at least one strand of about 23 contiguous deoxyribonucleotide bases.

6 . The composition of claim 1 , wherein the DNA oligonucleotide molecule is a single stranded DNA (ssDNA) molecule.

7 . The composition of claim 1 , wherein the DNA oligonucleotide is a double stranded DNA (dsDNA) molecule.

8 . The composition of claim 1 , wherein the composition comprises a plurality of the DNA oligonucleotide molecules, wherein each DNA oligonucleotide molecule comprises a unique sequence of deoxyribonucleotide bases relative to other DNA oligonucleotide molecules in the plurality.

9 . The composition of claim 1 , further comprising a pharmaceutically acceptable carrier.

10 . The composition of claim 1 , further comprising a liposome, a nanoparticle, a micelle or an exosome, wherein the DNA oligonucleotide molecule is contained in the liposome, nanoparticle, micelle or exosome.

11 . The composition of claim 1 , wherein the concentration of DNA oligonucleotide molecules in the composition is at least about 50 nM.

12 . The composition of claim 1 , wherein the concentration of the DNA oligonucleotide molecules in the composition is at least about 300 nM.

13 . A method for treating cancer in a subject in need thereof, comprising the step of administering to the subject an effective amount of a DNA oligonucleotide molecule, wherein the DNA oligonucleotide molecule comprises two or more phosphorothioate linkages, and wherein the DNA oligonucleotide molecule comprises at least one strand of more than 10 contiguous deoxyribonucleotide bases.

14 . The method of claim 13 , wherein the DNA oligonucleotide molecule comprises a 2′-O-methyl RNA base at the 5′ end, the 3′ end or both the 5′ and 3′ ends of at least one strand of the DNA oligonucleotide molecule.

15 . The method of claim 13 , wherein the DNA oligonucleotide molecule comprises a phosphorothioate linkage between each of the nucleotide bases of at least one strand of the DNA oligonucleotide molecule.

16 . The method of claim 13 , wherein administration of the DNA oligonucleotide molecule inhibits proliferation of cancer cells in the subject.

17 . The method of claim 13 , wherein administration of the DNA oligonucleotide molecule activates one or more immune system pathways in the subject.

18 . The method of claim 17 , wherein the immune system pathway is a RNase L pathway.

19 . The method of claim 13 , further comprising administering one or more additional therapeutic agents to the subject.

20 . The method of claim 19 , wherein the one or more additional therapeutic agents include a chemotherapeutic agent.

21 . The method of claim 19 , wherein the one or more additional therapeutic agents include an immunomodulatory agent.

22 . The method of claim 13 , wherein the DNA oligonucleotide molecule is a single stranded DNA (ssDNA) molecule.

23 . The method of claim 13 , wherein the DNA oligonucleotide molecule is a double stranded DNA (dsDNA) molecule.

24 . A method for activating an RNase L enzyme in a cell, comprising the step of contacting the cell with an effective amount of a DNA oligonucleotide molecule, wherein the DNA oligonucleotide molecule comprises two or more phosphorothioate linkages, and wherein the DNA oligonucleotide molecule comprises at least one strand of more than 10 contiguous deoxyribonucleotide bases.

25 . The method of claim 24 , wherein the DNA oligonucleotide molecule comprises a 2′-O-methyl RNA base at the 5′ end, the 3′ end or both the 5′ and 3′ ends of at least one strand of the DNA oligonucleotide molecule.

26 . The method of claim 24 , wherein the cell is a cancer cell.

27 . The method of claim 24 , wherein the cell is a virus-infected cell.

28 . The method of claim 24 , wherein the DNA oligonucleotide molecule is a single stranded DNA (ssDNA) molecule.

29 . The method of claim 24 , wherein the DNA oligonucleotide molecule is a double stranded DNA (dsDNA) molecule.

Assignees

• Univ Princeton

Inventors

• Chitrakar Alisha
• Korennykh Alexei

Classifications

• C12N15/1137 Primary

  against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138) · CPC title

• C12N2310/344

  Position-specific modifications, e.g. on every purine, at the 3'-end · CPC title

• C12N2310/17

  Immunomodulatory nucleic acids · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• C12N15/117 Primary

  Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs · CPC title